Studying Diabetic Retinopathy?

Check out How Neuromic's Tools Are Used

The authors used four of Neuromics to complete this study-

Sulodexide reduces glucose induced senescence in human retinal endothelial cells A. Gericke, K. Suminska-Jasińska & A. Bręborowicz Scientific Reports volume 11, Article number: 11532 (2021) Cite this article.

Material and Methods

Experiments were performed on HREC (#HEC09, Neuromics, Edina, MN, USA) in in vitro culture. Cells were seeded in 75 cm² culture flasks coated with AlphaBioCoat Solution (#AC00, Neuromics, Edina, MN, USA) and were grown in Endo Growth Medium (EKG001, Neuromics, Edina, MN, USA) supplemented with fetal bovine serum 0.5% until they formed monolayers. Then the cells were harvested with cell detachment solution (#ADF001, Neuromics, Edina, MN, USA) and seeded in quadruplicates into 25 cm² coated, as described above, culture flasks at a density of 1.5 × 10⁵ cells/flask.

We conclude that Sulodexide may have a beneficial effect in cases of diabetic retinopathy. It slows down hyperglycemia-dependent senescence of endothelial cells, which translates into the lower angiogenic and inflammatory impact of these cells. An important observation was that Sulodexide also has effective antiangiogenic and anti-inflammatory effects in the senescent HREC. That means that Sulodexide may be effective in retinal endothelial cells, which are already senescent. Further studies are required to explain the potential effect of Sulodexide on the endothelial glycocalyx structure and permeability of the retinal endothelial layer composed of the senescent cells to molecules with various size and electrical charge.

We are pleased to see our solutions used in this important  study. It could lead to drugs that slow diabetic retinopathy.